Actionable genetic alterations that are treatable with therapeutic agents have been identified in approximately 50% of lung adenocarcinomas and include mutations in EGFR, ERBB2, KRAS, ALK, BRAF, PIK3CA, AKT1, ROS1, NRAS, and MAP2K1[4]. This evidence concerns the gene EGFR and lung adenocarcinoma.